Bristol Myers Squibb (CELG-RI) Short term Debt (2009 - 2026)
Bristol Myers Squibb (CELG-RI) posted quarterly Short term Debt of $1.0 billion for Q2 2026, down 78.22% year-over-year from $4.7 billion in Q2 2025, and down 55.5% quarter-over-quarter from $2.3 billion in Q1 2026.
Bristol Myers Squibb (CELG-RI) Short term Debt (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has reported Short term Debt for 18 consecutive years, with $1.0 billion the latest figure, recorded in Q2 2026.
- In Q2 2026, Short term Debt fell 78.22% year-over-year to $1.0 billion; the TTM figure through Jun 2026 stood at $1.0 billion (down 78.22% YoY), while the FY2025 annual figure was $2.3 billion, up 10.51% from the prior year.
- Short term Debt retreated to $1.0 billion in Q2 2026 per CELG-RI's latest filing, from $2.3 billion in the prior quarter.
- Across five years, Short term Debt topped out at $7.5 billion in Q1 2022 and bottomed at $1.0 billion in Q2 2026.
- Historically, Short term Debt has averaged $3.6 billion across 5 years, with a median of $3.3 billion in 2023.
- Annual changes were most pronounced in 2022 — Short term Debt surged 323.3% — and 2024, when it sank 80.28%.
- Bristol Myers Squibb's Short term Debt stood at $4.3 billion in 2022, then fell by 26.85% to $3.1 billion in 2023, then slumped by 34.4% to $2.0 billion in 2024, then advanced by 10.51% to $2.3 billion in 2025, then plunged by 54.58% to $1.0 billion in 2026.
- Business Quant data shows CELG-RI's Short term Debt at $1.0 billion in Q2 2026, $2.3 billion in Q1 2026, and $2.3 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Bristol Myers Squibb | 224.21 Mn | -10.84 Bn | 9.25 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.03 Bn |
| Mar 31, 2026 | 2.31 Bn |
| Dec 31, 2025 | 2.26 Bn |
| Sep 30, 2025 | 4.51 Bn |
| Jun 30, 2025 | 4.72 Bn |
| Mar 31, 2025 | 3.55 Bn |
| Dec 31, 2024 | 2.05 Bn |
| Sep 30, 2024 | 1.08 Bn |
| Jun 30, 2024 | 3.53 Bn |
| Mar 31, 2024 | 6.19 Bn |
| Dec 31, 2023 | 3.12 Bn |
| Sep 30, 2023 | 5.47 Bn |
| Jun 30, 2023 | 3.02 Bn |
| Mar 31, 2023 | 2.75 Bn |
| Dec 31, 2022 | 4.26 Bn |
| Sep 30, 2022 | 2.13 Bn |
| Jun 30, 2022 | 4.95 Bn |
| Mar 31, 2022 | 7.52 Bn |
| Dec 31, 2021 | 4.95 Bn |
| Sep 30, 2021 | 5.07 Bn |